載入...
4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
BACKGROUND: Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. PURPOSE: To compare the effectiveness of AA and enzalutamide in patients with mCRPC. MATERIAL A...
Na minha lista:
| 發表在: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Group
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535815/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.219 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|